Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients

Valsaraj, Sona; Augusti, K. T.; Chemmanam, Varghese; Jose, Regi

doi:10.1007/s12291-009-0031-0

Cited by 3 publications

(2 citation statements)

References 15 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 In this context, the efficacy of liraglutide on lipid profile is well documented, 17 whereas inconsistent data exist about the efficay of glimepiride. [18][19][20] Our data in the present study indicate that both drugs cause a significant reduction in total blood cholesterol levels, whereas they show no effects on other lipid parameters. Also, the results indicate that liraglutide causes a significant decrease in systolic and diastolic BP, which is consistent with previous results.…”

Section: Discussionsupporting

confidence: 43%

Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy

Chiefari

Capula

Vero

et al. 2015

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 43%

Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy

Chiefari

Capula

Vero

et al. 2015

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Fluid retention is due to activity of Na + ions in the distal part of nephron. Which can be controlled by K-sparing diuretic [29][30][31][32][33][34] . Some specific types of cancers were associated with TZDs.…”

Section: Thiazolidinedionesmentioning

confidence: 99%

Pharmacotherapy of Diabetes Mellitus Type 2: A Review on Various Hypoglycemics

Khan

Baig

2022

JCNR

View full text Add to dashboard Cite

Diabetes is a cosmopolitan medical issue ramifying a large population regardless of ethnicity. Elevated glycemic condition in a patient is explained as diabetes. It can be mainly categorized into Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Insulin Dependent Diabetes Mellitus (IDDM) or Type 1 or Type 2 respectively. Type 1 or IDDM needs insulin therapy exclusively while Type 2 can be controlled via various hypoglycemic agents. Conventional classes contain glitazones, biguanides, sulfonylurea’s and so on, while newly developed drug classes include gliptins or DPP-4 inhibitors, SGLT-2 receptor inhibitors and GLP-1 receptor agonists. The novelty in the anti-hyperglycemic agents have given promising results as compared to the conventional drugs. Insulin cannot be negated as far as its glycemic control is concerned. Furthermore, development of Insulin analogues like detemir, glargine, Lispro have been shown to control glucose levels in the plasma more efficiently.

show abstract

A Comparative Study of Metformin alone, in Combination with Insulin or Metformin Plus Insulin in Presence of Simvastatin in Libyan Diabetic Patients

Menesi¹,

Sherif²,

ElGharadwi³

et al. 2017

PPIJ

View full text Add to dashboard Cite

Type 2 of diabetes mellitus (DM) is associated with progressive failure of pancreatic B-cells to secrete insulin, decreased insulin action, due to reduced insulin receptors at the target sites. Dyslipidemia is a common risk of DM and is responsible to a large extent for cardiovascular disease-related morbidity and mortality. This study was planned to compare the effects of metformin alone and a combination of metformin and insulin in presence of simvastatin on glycemic and lipid levels in Libyan diabetic patients. This retrospective study was conducted at Benghazi Diabetic Center (Libya) on 100 patients with type 2 DM of 40-60 years old. Patients were selected for follow up on basis of inclusion and exclusion criteria, and were divided into three groups. The first group (n=30), received metformin (1-2 gm/day). The second group (n=40) received metformin (1-2 gm/day) and insulin (mixtard 30/70, 30-60 units/day) and third group (n=30) received metformin (1-2 gm/day), insulin (30-60 units/day) plus simvastatin (40 mg/day). Glucose blood levels (FBG, PPBG and HBA1c), lipid profile (TC, TG, HDL-C, LDL-C and AI), hepatic function (ALT, AST, ALP and Bilirubin) and renal function (creatinine and urea) were measured for each patient. All the patients had a good glycemic control with significant decrease in HbAc1 of metformin plus insulin treated group. No significant differences in lipid profile of metformin treated group and metformin plus insulin treated group were observed. Date revealed both significant increase in HDL-C and decrease in TC, LDL-C and atherogenic index levels but without any change in TG in metformin and insulin treated group as compared with metformin, insulin plus simvastatin treated group. All the findings of hepatic and renal functions were within the normal range except for bilirubin which significantly increased in metformin, insulin plus simvastatin treated group compared with other treated groups. In conclusion, the efficacy of metformin in controlling hyperglycemia was enhanced with insulin without negative effects. Simvastatin was effective in controlling dyslipidemia associated with DM and produced a profound reduction in TC and LDL-C of the patients.

show abstract

Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients

Abstract: ABSTRACT

Cited by 3 publications

References 15 publications

Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy

Add-On Treatment with Liraglutide Improves Glycemic Control in Patients with Type 2 Diabetes on Metformin Therapy

Pharmacotherapy of Diabetes Mellitus Type 2: A Review on Various Hypoglycemics

A Comparative Study of Metformin alone, in Combination with Insulin or Metformin Plus Insulin in Presence of Simvastatin in Libyan Diabetic Patients

Contact Info

Product

Resources

About